Literature DB >> 12468780

Low concentration of serum total cholesterol is associated with multifocal signal loss lesions on gradient-echo magnetic resonance imaging: analysis of risk factors for multifocal signal loss lesions.

Seung-Hoon Lee1, Hee-Joon Bae, Byung-Woo Yoon, Ho Kim, Dong-Eog Kim, Jae-Kyu Roh.   

Abstract

BACKGROUND AND
PURPOSE: Multifocal signal loss lesions (MSLLs) on T2*-weighted gradient-echo (GE) MRI are believed to be microbleeds histopathologically. Previous epidemiological studies suggested that low serum cholesterol is associated with the increased risk of intracerebral hemorrhage. We investigated risk factors of MSLLs and the relationship between lipid profiles and MSLLs on GE-MRI.
METHODS: We included consecutively 172 patients who underwent brain MRI. MSLLs on GE-MRI were counted by 2 neurologists separately and graded by consensus. The concentrations of lipid profiles were categorized as quartiles, and the MSLLs were graded as absent (total count, 0), mild (1 to 2), moderate (3 to 10), and severe (>10).
RESULTS: The mean concentrations of total cholesterol and low-density lipoprotein cholesterol were significantly lower in patients with a severe degree of MSLLs than in those without MSLL (P<0.05). By multivariate analysis, MSLLs were significantly correlated with hypertension (odds ratio [OR], 3.42; 95% CI, 1.17 to 9.97), leukoaraiosis (OR, 4.62; 95% CI, 2.87 to 7.41), the lowest quartile of serum total cholesterol (<4.27 mmol/L; OR, 10.91; 95% CI, 3.98 to 25.57), and the highest quartile of high-density lipoprotein (>1.47 mmol/L; OR, 3.5; 95% CI, 1.45 to 8.29).
CONCLUSIONS: Our results suggest that both the lipid profile levels and the severity of hypertension may be closely associated with MSLLs on GE-MRI.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12468780     DOI: 10.1161/01.str.0000036092.23649.2e

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  42 in total

1.  SPARCL: statin therapy for stroke patients is not crystal clear.

Authors:  Robert S Rosenson
Journal:  Curr Atheroscler Rep       Date:  2007-09       Impact factor: 5.113

2.  Lipid Control and Beyond: Current and Future Indications for Statin Therapy in Stroke.

Authors:  Shadi Yaghi; Mitchell S V Elkind
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-04

3.  Association between carotid artery plaque type and cerebral microbleeds.

Authors:  L Saba; R Montisci; E Raz; R Sanfilippo; J S Suri; M Piga
Journal:  AJNR Am J Neuroradiol       Date:  2012-05-24       Impact factor: 3.825

4.  Low-Density Lipoprotein Cholesterol and Risk of Hemorrhagic Stroke: a Systematic Review and Dose-Response Meta-analysis of Prospective Studies.

Authors:  Chaoran Ma; Muzi Na; Samantha Neumann; Xiang Gao
Journal:  Curr Atheroscler Rep       Date:  2019-11-20       Impact factor: 5.113

Review 5.  The role of statins in neurosurgery.

Authors:  Jorge Humberto Tapia-Pérez; Martin Sanchez-Aguilar; Thomas Schneider
Journal:  Neurosurg Rev       Date:  2010-04-29       Impact factor: 3.042

6.  Frequency of asymptomatic microbleeds on T2*-weighted MR images of patients with recurrent stroke: association with combination of stroke subtypes and leukoaraiosis.

Authors:  Hiromitsu Naka; Eiichi Nomura; Shinichi Wakabayashi; Hiroshi Kajikawa; Tatsuo Kohriyama; Yasuyo Mimori; Shigenobu Nakamura; Masayasu Matsumoto
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

7.  Silent microbleeds and old hematomas in spontaneous cerebral hemorrhages.

Authors:  Jae-Bum Lim; Ealmaan Kim
Journal:  J Korean Neurosurg Soc       Date:  2009-07-31

8.  Comparison of ESWAN, SWI-SPGR, and 2D T2*-weighted GRE sequence for depicting cerebral microbleeds.

Authors:  L F Guo; G Wang; X Y Zhu; C Liu; L Cui
Journal:  Clin Neuroradiol       Date:  2012-12-03       Impact factor: 3.649

9.  SPARCL: the glimmer of statins for stroke risk reduction.

Authors:  Annemarie Armani; Peter P Toth
Journal:  Curr Atheroscler Rep       Date:  2007-11       Impact factor: 5.113

Review 10.  Atorvastatin: its clinical role in cerebrovascular prevention.

Authors:  Achille Gaspardone; Marcello Arca
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.